COI Disclosure I have no conflict of interest to disclose I have no conflict of interest to disclose.

Slides:



Advertisements
Similar presentations
M.Unverdorben; ACC March 2008 Martin Unverdorben Rotenburg/Fulda, Germany and Richmond, VA, USA Clinical Research Institute, Center for Cardiovascular.
Advertisements

Implications from PROSPECT and Future Directions Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Providing.
IVUS-VH & Vulnerable Plaque Jang-Ho Bae, MD., PhD. Heart Center Konyang University Hospital Daejeon City, S. Korea Jang-Ho Bae, MD., PhD. Heart Center.
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Types of blood vessels: Veins Arteries Common structures Tunica adventitia Tunica media Tunica intima Lumen.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
ASTEROID A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden   References Nissen et al. Effect.
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
Major Bleeding Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian,
BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.
Calculated LDL by Age Cases vs. Controls Figure 1.
Virtual Histology:From Theory to Vulnerable Plaque Detection Shaoliang Chen MD Nanjing First Hospital Nanjing Cardiovascular Hospital.
Calcium score as a predictor of coronary artery disease severity in patients with acute coronary syndromes Coordinator Author Prof.Dr.Benedek Theodora.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Relationship between total cholesterol and 90-day mortality after acute myocardial infarction in patients not on statins Rishi Parmar 2 nd year Medicine.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.
David Hildick-Smith Sussex Cardiac Centre. Background to ARTS Previous POBA studies Meta-analysis 3300 patients 1660 CABG, 1710 PTCA Deaths 79 PCI vs.
Effect of on Oral Agent Inducing ApoA-I Synthesis on Progression of Coronary Atherosclerosis: Results of the ASSURE Study SJ Nicholls, CM Ballantyne, PJ.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
New techniques for the “invasive diagnosis” of the vulnerable plaque Antwerp, 17 March 2006.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Assessment of Coronary Plaque Progression in Coronary.
Indication Contraindication Preparation
Ischaemic heart disease. Coronary artery disease(CAD) is the leading cause of death worldwide. The rates of mortality and disability due to CAD are increasing.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis: Insights from the GLAGOV Trial SJ Nicholls, H Kassahun, DM Brennan,
It’s Both the Vulnerable Patient and the Vulnerable Plaque
Near Infrared Spectroscopy: Case Studies and Clinical Relevance
Results from the intermountain heart collaborative study
Atherosclerosis and HDL Therapy New Virtual Histology Findings
Arabinda Mohan Bhattarai, MBBS, MD (Biochemistry) Asst Prof, NAIHS
Copyright © 2004 American Medical Association. All rights reserved.
9:00 AM-9:05 AM, Tuesday, Oct. 31; Room 201/203
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
On behalf of J. Belardi, M. Leon, L. Mauri,
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
Giuseppe Biondi Zoccai, MD
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Volume 82, Issue 3, Pages (August 2012)
Volume 383, Issue 9918, Pages (February 2014)
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
Figure 4 Change in plaque burden, plaque area, and plaque composition according to wall shear stress. (A and B) Change ... Figure 4 Change in plaque burden,
Gregg W. Stone, MD Columbia University Medical Center
Stephen J. Nicholls, MBBS, PhD; E
Flow Diagram of the Trial Selection Process
Atlantic Cardiovascular Patient Outcomes Research Team
Presentation transcript:

COI Disclosure I have no conflict of interest to disclose I have no conflict of interest to disclose

Calcium is Strongly Correlated with Necrotic Core in Human Coronary Arteries: Insights from the Multicenter VH-IVUS Registry Eduardo Missel, Gary S. Mintz, Stephane G. Carlier, Koichi Sano, Joanna Lui, Roxana Mehran, Jeffrey Moses, Gregg W. Stone, and Martin B. Leon Cardiovascular Research Foundation Columbia University Medical Center New York – NY - USA European Society of Cardiology Congress 2007 Vienna - Austria

I - Background Unstable and/or ruptured plaques: Unstable and/or ruptured plaques: - Larger necrotic core content (Histopathology) - Less quantitative calcium with a “spotty” pattern (IVUS) when compared to stable/non-ruptured plaques, HOWEVER… Calcification in the coronary tree is a predictor of coronary events (EBCT) Calcification in the coronary tree is a predictor of coronary events (EBCT) The “coronary calcification paradox”

II- Methods Allows spectral analysis of radiofrequency (RF) ultrasound backscatter; Allows spectral analysis of radiofrequency (RF) ultrasound backscatter; 80-92% ex-vivo and % in vivo accuracy for characterization of basic plaque components 80-92% ex-vivo and % in vivo accuracy for characterization of basic plaque components Virtual Histology Fibrous tissue (FI) Fibro-fatty (FF) Dense calcium (DC) Necrotic core (NC)

II - Methods Study protocol Study protocol Between August 2004 to July patients in 42 centers were enrolled in the prospective, multi-center, non-randomized VH- IVUS registry Between August 2004 to July patients in 42 centers were enrolled in the prospective, multi-center, non-randomized VH- IVUS registry We identified 625 patients with a de novo coronary lesion who were studied with either diagnostic or pre-interventional VH-IVUS. We identified 625 patients with a de novo coronary lesion who were studied with either diagnostic or pre-interventional VH-IVUS.

II - Methods VH-IVUS imaging protocol A phased-array, 20MHz, 3.2Fr IVUS catheter was placed at a branch distal to the lesion A phased-array, 20MHz, 3.2Fr IVUS catheter was placed at a branch distal to the lesion A motorized pull-back through the diseased segment was performed at 0.5mm/s to a point proximal to the lesion site A motorized pull-back through the diseased segment was performed at 0.5mm/s to a point proximal to the lesion site Grey-scale IVUS was recorded, raw RF data was captured at the top of the R wave, and a color-coded VH-IVUS map was generated Grey-scale IVUS was recorded, raw RF data was captured at the top of the R wave, and a color-coded VH-IVUS map was generated

II - Methods Data Analysis Off-line volumetric reconstruction of the four tissue types along the whole diseased segment was performed using pcVH 2.1 software Off-line volumetric reconstruction of the four tissue types along the whole diseased segment was performed using pcVH 2.1 software The four VH-IVUS plaque components were measured in every recorded frame, and expressed as The four VH-IVUS plaque components were measured in every recorded frame, and expressed as - Mean analysis segment CSA (mm2) - Absolute volume (mm3) - Percentages of total plaque volume (%)

III - Results Baseline patients characteristics (n=625) Age (years)62±11 Male gender, # (%)473 (76) Current smoker, # (%)157 (25) Lipid disorder, # (%)426 (68) Hypertension, # (%)401 (64) Family history of CHD, # (%)241 (39) Diabetes mellitus, # (%)146 (23) Prior myocardial infarction, # (%)150 (24) Prior bypass surgery, # (%)39 (6) Congestive heart failure, # (%)38 (6) Acute Coronary Syndrome, # (%)273 (44) Unstable Angina, # (%)164 (26) Non-Q-wave MI, # (%)62 (10) Acute MI, # (%)48 (8)

III - Results Target Vessel

III - Results Grey-scale IVUS parameters (n=625) Pullback length (mm)48.6±20.9 Mean lumen CSA (mm 2 )8.60±2.87 Mean EEM CSA (mm 2 )15.40±4.71 Average P&M CSA (mm 2 )6.80±2.79 Lumen volume (mm 3 )412.87± EEM volume (mm 3 )741.97± Plaque volume (mm 3 )329.10± Mean plaque burden (%)43.57±9.33

III - Results VH-IVUS parameters (n=625) Mean fibrous plaque CSA (mm 2 )2.16±1.45 Mean fibro-fatty plaque CSA (mm 2 )0.73±0.62 Mean necrotic core CSA (mm 2 )0.43±0.41 Mean dense calcium CSA (mm 2 )0.29±0.34 Fibrous plaque volume (mm 3 )104.99±87.75 Fibro-fatty plaque volume (mm 3 )34.79±33.18 Necrotic core volume (mm 3 )20.42±20.03 Dense calcium volume (mm 3 )13.86±17.65 % Fibrous volume28.81±9.68 % Fibro-fatty volume9.59±5.54 % Necrotic core volume5.74±3.78 % Calcified volume3.83±3.49

III - Results Relationship between NC and DC (n=625) Relationship between NC and DC (n=625) r=0.81 r 2 =0.68 P<0.0001

III - Results Lipid Profile ParametersNC/DC ratiop MedianIQR Male GenderYes1.79[ ]0.04 No1.60[ ] DiabetesYes1.63[ ]0.08 No1.58[ ] SmokingYes1.96[ ]0.007 No1.65[ ] HypertensionYes1.86[ ]0.06 No1.65[ ] Family history of CHD Yes1.82[ ]0.51 No1.70[ ] NC/DC ratio and risk factors (n=625) NC/DC ratio and risk factors (n=625)

III - Results Lipid Profile ParametersNC/DC ratiop MedianIQR Male GenderYes1.79[ ]0.04 No1.60[ ] DiabetesYes1.63[ ]0.08 No1.58[ ] SmokingYes1.96[ ]0.007 No1.65[ ] HypertensionYes1.86[ ]0.06 No1.65[ ] Family history of CHD Yes1.82[ ]0.51 No1.70[ ] NC/DC ratio and risk factors (n=625) NC/DC ratio and risk factors (n=625)

III - Results Lipid Profile ParametersNC/DC ratiop MedianIQR Total Cholesterol>200mg/dl1.83[ ]0.08 ≤200mg/dl1.68[ ] LDL-C≥100mg/dl1.79[ ]0.003 <100mg/dl1.58[ ] HDL-C<50mg/dl1.78[ ]0.22 ≥50mg/dl1.63[ ] TC/HDL ratio≥51.98[ ]0.006 <51.67[ ] Triglycerides≥150mg/dl1.92[ ]0.005 <150mg/dl1.66[ ] NC/DC ratio and serum lipid cutoffs (n=625) NC/DC ratio and serum lipid cutoffs (n=625)

III - Results Lipid Profile ParametersNC/DC ratiop MedianIQR Total Cholesterol>200mg/dl1.83[ ]0.08 ≤200mg/dl1.68[ ] LDL-C≥100mg/dl1.79[ ]0.003 <100mg/dl1.58[ ] HDL-C<50mg/dl1.78[ ]0.22 ≥50mg/dl1.63[ ] TC/HDL ratio≥51.98[ ]0.006 <51.67[ ] Triglycerides≥150mg/dl1.92[ ]0.005 <150mg/dl1.66[ ] NC/DC ratio and serum lipid cutoffs (n=625) NC/DC ratio and serum lipid cutoffs (n=625)

III - Results Independent predictors of p-Value NC/DC ratio: Admission hs-CRP p=0.007 LDL-C p=0.03 -Age, smoking, hypertension p=NS -Stepwise regression was performed -HDL-C, TG, previous history of CHD and diabetes were dropped from the analysis

III - Results NC/DC ratio and LDL-C Quartiles (n=625) NC/DC ratio and LDL-C Quartiles (n=625) p=0.005

III - Results NC/DC ratio and TC/HDL Quartiles (n=625) NC/DC ratio and TC/HDL Quartiles (n=625) p=0.003

IV - Conclusions Calcium has a strong correlation with necrotic core in human coronary arteries Calcium has a strong correlation with necrotic core in human coronary arteries The NC/DC ratio has a significant positive association with an adverse lipid profile, and smoking The NC/DC ratio has a significant positive association with an adverse lipid profile, and smoking

IV - Conclusions Even though calcium is not prominent within lesions of ACS patients, more calcium indicates larger and/or more numerous necrotic cores Even though calcium is not prominent within lesions of ACS patients, more calcium indicates larger and/or more numerous necrotic cores These findings are consistent with the concept that an EBCT calcium score is able to predict further coronary events These findings are consistent with the concept that an EBCT calcium score is able to predict further coronary events